Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling-Reference-Cited by-同舟云学术

Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt–β-catenin signaling

Published:2013-03-07 Issue:10 Volume:121 Page:1824-1838
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Zhang Bin¹,Li Min²,McDonald Tinisha¹,Holyoake Tessa L.³,Moon Randall T.⁴,Campana Dario⁵,Shultz Leonard⁶,Bhatia Ravi¹

Affiliation:

1. Division of Hematopoietic Stem Cell and Leukemia Research, Beckman Research Institute,

2. Department of Information Sciences, City of Hope Cancer Center, Duarte, CA;

3. College of Medical, Veterinary & Life Sciences, Institute of Cancer Sciences, University of Glasgow, Scotland, United Kingdom;

4. Department of Pharmacology, University of Washington, Howard Hughes Medical Institute, Seattle, WA;

5. University Children’s Medical Centre, National University of Singapore, Singapore; and

6. The Jackson Laboratory, Bar Harbor, ME

Abstract

Key Points Bone marrow mesenchymal stromal cells preserve CML stem cells from elimination following tyrosine kinase inhibitor treatment. N-cadherin and Wnt signaling contribute to protection of CML stem cells by mesenchymal cells and may represent new treatment targets.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/121/10/1824/1363196/1824.pdf

Reference50 articles.

1. Chronic myeloid leukemia.;Sawyers;N Engl J Med,1999

2. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.;Druker;N Engl J Med,2006

3. Imatinib and beyond—exploring the full potential of targeted therapy for CML.;Quintás-Cardama;Nat Rev Clin Oncol,2009

4. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.;Mahon;Lancet Oncol,2010

5. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment.;Chu;Blood,2011

Cited by 222 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Concomitant targeting of FLT3 and SPHK1 exerts synergistic cytotoxicity in FLT3-ITD+ acute myeloid leukemia by inhibiting β-catenin activity via the PP2A-GSK3β axis;Cell Communication and Signaling;2024-08-07

2. Do tunneling nanotubes drive chemoresistance in solid tumors and other malignancies?;Biochemical Society Transactions;2024-07-19

3. Cadherin-11 contributes to the heterogenous and dynamic Wnt-Wnt-β-catenin pathway activation in Ewing sarcoma;PLOS ONE;2024-06-14

4. Targeting histone deacetylase 1 (HDAC1) in the bone marrow stromal cells revers imatinib resistance by modulating IL-6 in Ph + acute lymphoblastic leukemia;Annals of Hematology;2024-06-07

5. Decreased NMIIA heavy chain phosphorylation at S1943 promotes mitoxantrone resistance by upregulating BCRP and N-cadherin expression in breast cancer cells;Biochemistry and Cell Biology;2024-06-01